Wu Angela, Brown Danielle, Wong Uni
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland.
Gastro Hep Adv. 2022 Nov 11;2(3):322-324. doi: 10.1016/j.gastha.2022.11.007. eCollection 2023.
Infliximab is a chimeric monoclonal antibody to tumor necrosis factor-α used commonly in several autoimmune conditions including Crohn's disease. We present a case of a 33-year-old man with inflammatory ileocolonic Crohn's disease who developed biopsy-proven leukocytoclastic vasculitis (LCV) exacerbated by a rechallenged dose of infliximab after years of tolerating the drug. To our knowledge, this is the first reported case of infliximab-associated LCV that occurred years after initiation of the drug. This case highlights that LCV can be a potential adverse reaction of infliximab, and health-care providers should consider a change in therapy.
英夫利昔单抗是一种针对肿瘤坏死因子-α的嵌合单克隆抗体,常用于包括克罗恩病在内的多种自身免疫性疾病。我们报告一例33岁患有炎症性回结肠克罗恩病的男性病例,该患者在耐受该药多年后,因再次使用英夫利昔单抗剂量而引发经活检证实的白细胞破碎性血管炎(LCV)。据我们所知,这是首次报道在开始使用该药数年之后发生的英夫利昔单抗相关LCV病例。该病例突出表明,LCV可能是英夫利昔单抗的一种潜在不良反应,医疗保健人员应考虑改变治疗方法。